Join to View Full Profile
6400 Sanger RdSte A-2400Orlando, FL 32827
Phone+1 407-735-5695
Fax+1 407-851-4630
Dr. Velez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Miami Hospital and Clinics/Holy Cross HospitalResidency, Internal Medicine, 2008 - 2011
Universidad del Norte Faculty of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2014 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Characterization of plasma cell-free DNA variants as of tumor- or clonal hematopoiesis-origin in 16,812 advanced cancer patients.Daniel Magee, Valeriy Domenyuk, Jim Abraham, Nieves Perdigones Borderias, Jeff Swensen
Clinical Cancer Research. 2025-02-11 - 3 citationsEGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.Luis E. Raez, Carlos Carracedo, Leylah M. Drusbosky, Michel Velez, Jennifer W Carlisle
Clinical Lung Cancer. 2021-04-09 - 1 citationsEvaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.Aurelio Castrellon, Michel Velez, Steven M. Nguyen, Marcelo Blaya, Sandra Barnick
Hematology/oncology and Stem Cell Therapy. 2017-10-01
Press Mentions
UCF’s Cancer Center in Lake Nona Begins Taking Shape as Florida Cancer Specialists Finds New HomeFebruary 24th, 2021- Florida Cancer Specialists & Research Institute Welcomes Dr. Michel VelezDecember 28th, 2020
Key Trials Showcase the Utility of Neratinib in HER2+ Breast CancerAugust 9th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
